MNOV — MEDICINOVA INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1226616 ·
Last close
$1.52
Market Cap
$74.82M
52W High
$3.90
52W Low
$1.17
ADV30
644,382
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 458,439 | 317,759 | -2,541,189 | -2,314,139 | 40,433,469 | 25,415,921 | 3,162,867 |
| Mar 2026 | 186,984 | 16,883 | -2,835,806 | -2,586,258 | 42,704,854 | 27,329,415 | 3,297,620 |
| Dec 2025 | 151,739 | 4,754 | -3,092,402 | -2,802,279 | 45,603,109 | 30,806,477 | 4,016,428 |
| Sep 2025 | 123,319 | 8,047 | -3,380,998 | -3,050,373 | 47,578,388 | 32,562,612 | 3,613,632 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,496,613
Investing CF
$-13,724
Financing CF
—
CapEx
$-10,825
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.24
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-441,335,457
Inventory
—
Receivables
$245,100
ST Investments
—
EBIT TTM
$-12,916,298
Pretax Income TTM
$-11,714,101
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$920,481
EBITDA
$-11,831,257
Free Cash Flow
$-5,738,905
Enterprise Value
$63,791,572
Total Cash
$25,415,920
Total Debt
$117,038
Shares Out
49,221,246
Trailing EPS
$-0.21
Book Value
$0.76
ROE
-25.6%
ROA
-16.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 409,657 | -13,283,002 | -11,997,957 | 45,603,109 | 4,016,428 | 41,586,681 | -9,810,061 |
| Dec 2024 | 0 | -12,675,331 | -11,049,549 | 55,875,926 | 3,372,375 | 52,503,551 | -10,642,964 |
| Dec 2023 | 1,000,000 | -9,900,265 | -8,571,516 | 66,269,977 | 3,891,553 | 62,378,424 | -7,431,038 |
| Dec 2022 | 0 | -14,628,649 | -14,069,083 | 74,154,905 | 3,912,870 | 70,242,035 | -12,911,563 |
TTM Snapshot
Revenues TTM
$596,641
NetIncome TTM
$-11,720,095
OpCashFlow TTM
—
Assets (Latest)
$42,704,854
Forward EPS
$-0.45
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.52 · call volume: 1 · put volume: 42
Expected Move to 2026-10-16:
±$0.68
(44.41%) —
implied range
$0.84 –
$2.19
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LFVN | Lifevantage Corp | $75.16M | $6.00 | — |
| MAIA | MAIA Biotechnology, Inc. | $74.22M | $1.22 | — |
| OSTX | OS Therapies Inc | $75.82M | $1.62 | — |
| NMAD | NOMAD POWER SOLUTIONS, INC. | $72.94M | $4.53 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $77.03M | $1.12 | — |
News headlines (Yahoo Finance, 1h cache)
MediciNova to Participate in the Maxim Growth Summit
2026-10-06 10:00 · Yahoo
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
2026-09-28 15:10 · Yahoo
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
2026-09-28 13:58 · Yahoo
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
2026-09-28 13:20 · Yahoo
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2026-09-28 10:00 · Yahoo
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
2026-09-24 10:00 · Yahoo
MediciNova to Participate in Two Investor Conferences in September
2026-09-08 10:00 · Yahoo
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
2026-07-15 12:00 · Yahoo
MediciNova CEO Provides Shareholder Update
2026-06-30 12:00 · Yahoo
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
2026-06-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.